1. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD) – a EAACI position paper. Allergy 2019; 74: 28-39.
2.
Rajan JP, Wineinger NE, Stevenson DD, et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 2015; 135: 676-81.
3.
Bavbek S, Dursun B, Dursun E, et al. The prevalence of aspirin hypersensitivity in patients with nasal polyposis and contributing factors. Am J Rhinol Allergy 2011; 25: 411-5.
4.
Szczeklik A, Niżankowska E, Duplaga M; AIANE investigatiors. Natural history of aspirin-induced asthma. Eur Respir J 2000; 16: 432-6.
5.
Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical chracteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89: 474-8.
6.
Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with difficult-to treat asthma. J Allergy Clin Immunol 2005; 116: 970-5.
7.
Stevens WW, Peters AT, Hirsch AG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2017; 5: 1061-70e3.
8.
Mullol J, Boyce J, Dahlen SE, et al. Eicosanoid dysregulation and type 2 inflammation in AERD. J Allergy Clin Immunol 2021; 148: 1157-60.
9.
Sehanobish E, Asad M, Barbi M, et al. Aspirin actions in treatment of NSAID-exacerbated respiratory disease. Front Immunol 2021; 12: 695815.
10.
Steinke JW, Payne SC, Borish L. Eosinophils and mast cells in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am 2016; 36: 719-34.
11.
Jakiela B, Soja S, Sladek K, et al. Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease. J Allergy Clin Immunol 2021; 147: 1318-28e5.
12.
Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020; 146: 595-605.
13.
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394: 1638-50.
14.
Laidlaw TM, Buchheit KM, Cahill KM, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR. J Allergy Clin Immunol Pract 2025; 13: 1855-8e2.
15.
Hayashi H, Mitsui C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2016; 137: 1585-7.
16.
Hayashi H, Fukutomi Y, Mitsui C, et al. Omalizumab for aspirin hypresensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial. Am J Respir Crit Care Med 2020; 201: 1488-98.
17.
Quint T, Dahm V, Arnoldner MA, et al. Omalizumab-induced aspirin tolerance in non-steroidal anti-inflammatory drug-exacerbated respiratory disease patients is independent of atopic sensitization. J Allergy Clin Immunol 2022; 10: 506-16.
18.
Hayashi H, Fukutomi Y, Mitsui C, et al. Omalizumab ameliorated extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2023; 151: 1667-72.
19.
Boyce JA. Aspirin sensitivity: lessons in the regulation and dysregulation of mast cell function. J Allergy Clin Immunol 2019; 144: 875-81.
20.
Buchheit KM, Sohail A, Hacker J, et al. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2022; 150: 415-24.
21.
Schneider S, Poglitsch K, Morgenstern C, et al. Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease. Eur Respir J 2023; 61: 2201335.
22.
Steinke JW, Payne SC, Borish L. Interleukin-4 in the generation of the AERD phenotype: implications for molecular mechanisms driving therapeutic benefit of aspirin desensitization. J Allergy (Cairo) 2012: 182090.
23.
Hayashi Y, Kouyashi M, Kuwata H, et al. Interferon gamma and interleukin 4 inhibit interleukin 1-beta induced delayed prostaglandin E2 generation through suppression of cyclooxgenase 2 expression in human fibroblasts. Cytokine 2000; 12: 601-12.
24.
Picado C, Mulloll J, Roca-Ferrer J. Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: a hypothesis. J Allergy Clin Immunol 2023; 151: 310-3.
25.
Martin H, Barrett NA, Laidlaw T. Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2020; 9: 1384-5.
26.
Sanchez J, Garcia E, Lopez JF, et al. Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: a randomized comparative trial. J Allergy Clin Immunol Pract 2023; 11: 2172-9.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
